Cortagen has shown to be a correcting agents for functional and metabolic disorders in the brain caused by chronic ischemia. In an experiment with ischemic rats, both drugs were found to accelerate the recovery of individual behavior and prevent excessive activation of lipid peroxidation and decrease in antioxidant activity in brain tissues. These results suggest that cortexin and cortagen may be useful for improving the efficacy of neuroprotective therapy in cases of chronic brain ischemia. Additionally, it has been observed that cortagen has therapeutic effects on posttraumatic recovery of peripheral nerve tissue, as well as on cardiovascular and cerebrovascular parameters in humans.
Zarubina IV, Shabanov PD. [Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia]. Eksp Klin Farmakol. 2011;74(2):8-15. Russian. PMID: 21476278.
Anisimov SV, Khavinson VKh, Anisimov VN. Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray. Neuro Endocrinol Lett. 2004 Feb-Apr;25(1-2):87-93. PMID: 15159690.
ALL ARTICLE AND PRODUCT INFORMATION ON THIS WERBSITE IS PROVIDED FOR INFORMATIONAL PURPOSE ONLY.
The products offered are intended for in-vitro studies exclusively and are not medicine, drugs, or FDA-approved substances to prevent, treat, or cure any medical condition, ailment, or disease. By law, the introduction of these products into the human or animal body is strictly forbidden. The website owners, operators, and contributors cannot be held liable for any consequences resulting from the use or reliance on the information or products. Users are responsible for complying with applicable laws and regulations.